Momelotinib is a JAK1/JAK2 inhibitor, which in murine models of anemia in chronic disease, was shown to inhibit bone morphogenic protein receptor kinase activin A receptor type I (ACVR1)–mediated hepcidin expression, which stimulated erythropoiesis [81]. Here, ACVR1 is linked to anemia.